Acta Haematologica最新文献_第2页

Kundalini Yoga for Improving Patient-Reported Outcomes in Patients Diagnosed with Myelodysplastic Syndromes: A Pilot Study. 昆达里尼瑜伽改善骨髓增生异常综合征患者报告的预后：一项初步研究

IF 1.1 4区医学

Acta Haematologica Pub Date : 2025-08-20 DOI: 10.1159/000547575

Irina Amitai, Ronit Marcus, Yoav Amitai, Abraham Avigdor, Drorit Merkel

{"title":"Kundalini Yoga for Improving Patient-Reported Outcomes in Patients Diagnosed with Myelodysplastic Syndromes: A Pilot Study.","authors":"Irina Amitai, Ronit Marcus, Yoav Amitai, Abraham Avigdor, Drorit Merkel","doi":"10.1159/000547575","DOIUrl":"10.1159/000547575","url":null,"abstract":"Introduction: Despite adequate pharmacologic treatment and transfusion support for myelodysplastic syndromes (MDS), there is an ongoing need to explore non-pharmacologic approaches for managing MDS symptom burden. Yoga has proved effective in oncologic patients. The aim of this observational study was to explore the feasibility of an 8-week online Kundalini yoga program, including its impact on symptom burden in MDS patients.Methods: All patients diagnosed with MDS in our medical center were offered an 8-week online program, in which a 1-h weekly kundalini yoga session was held live via Zoom. All segments included postures in the sitting position, specifically planned for this patient population. Symptom burden was assessed before and after each session and at a later timepoint - 8 weeks post-course completion, using the Edmonton Symptom Self-Assessment Scale - global distress score (ESAS-GDS).Results: Fourteen patients participated in the program. The median number of sessions per patient was 4. The questionnaires were reasonably easy for the patients to complete. Mean GDSs significantly improved after yoga sessions. Patients consistently endorsed reduced fatigue (78%), increased alertness (65%), increased general well-being (60%), and reduced anxiety (42%) after practicing yoga. Furthermore, symptom burden remained significantly improved 8 weeks after course completion.Conclusion: This Kundalini yoga program for MDS patients was feasible and resulted in significantly better patient-reported health outcomes, ongoing for at least 8 weeks after the last intervention. Longer follow-up within a longer practice program is planned.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-6"},"PeriodicalIF":1.1,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144938306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-World Insights into Avatrombopag's Effectiveness and Safety in Adults with Primary Immune Thrombocytopenia: A Retrospective Analysis from Central and Eastern Europe. Avatrombopag对原发性免疫性血小板减少症成人的有效性和安全性的真实世界见解：来自中欧和东欧的回顾性分析

IF 1.1 4区医学

Acta Haematologica Pub Date : 2025-08-13 DOI: 10.1159/000547576

Barbara Skopec, Dražen Pulanić, Libor Červinek

{"title":"Real-World Insights into Avatrombopag's Effectiveness and Safety in Adults with Primary Immune Thrombocytopenia: A Retrospective Analysis from Central and Eastern Europe.","authors":"Barbara Skopec, Dražen Pulanić, Libor Červinek","doi":"10.1159/000547576","DOIUrl":"10.1159/000547576","url":null,"abstract":"Introduction: Primary immune thrombocytopenia (ITP) is an autoimmune condition marked by low platelet counts, leading to symptoms such as bleeding. Avatrombopag (AVA), a second-generation thrombopoietin receptor agonist, has shown efficacy in clinical trials but lacks extensive real-world data, particularly in Central and Eastern Europe (CEE). This study aims to evaluate the effectiveness and safety of AVA in routine clinical practice for ITP patients across CEE countries.Methods: A multicenter, noninterventional, retrospective analysis was conducted in Slovenia, Croatia, and the Czech Republic, involving 41 patients treated with AVA for primary ITP. The primary endpoint was achieving a platelet response at week 8 (W8).Results: AVA treatment resulted in a 68.3% platelet response rate by W8, with a significant increase in median platelet counts. Rescue medication use decreased post-AVA initiation, and many patients reduced or discontinued steroids. AVA was well-tolerated, with only one adverse event reported and no significant bleeding events.Conclusion: AVA is effective in improving platelet counts and reducing medication dependency in ITP patients in CEE countries. It offers a viable treatment option with a favorable safety profile, supporting its use across different ITP stages and patient demographics.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-11"},"PeriodicalIF":1.1,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Approach to Hairy-Cell Leukemia in the New Therapeutic Era with Special Emphasis on Age and Comorbidities. 新治疗时代毛细胞白血病的治疗方法，特别强调年龄和合并症。

IF 1.1 4区医学

Acta Haematologica Pub Date : 2025-08-04 DOI: 10.1159/000547722

Ilana Levy Yurkovski, Tamar Tadmor

{"title":"Approach to Hairy-Cell Leukemia in the New Therapeutic Era with Special Emphasis on Age and Comorbidities.","authors":"Ilana Levy Yurkovski, Tamar Tadmor","doi":"10.1159/000547722","DOIUrl":"10.1159/000547722","url":null,"abstract":"Background: Hairy-cell leukemia (HCL) is a rare chronic hematologic malignancy, generally presenting with pancytopenia, relative lymphocytosis, monocytopenia, and splenomegaly. Diagnosis is based on typical bone marrow evaluation with the BRAF-V600E mutation being present in almost 100% of cases of classical HCL.Summary: Treatment usually involves the use of purine analogs (PAs) as first-line therapy. Novel targeting therapies have recently been included in the treatment of therapy-naive HCL such as PA combination with anti-CD20, BRAF inhibitors alone, or combined with anti-CD20. In relapse/refractory disease, other novel agents were studied as BRAF and MEK inhibitors, Bruton tyrosine kinase, or BCL2 inhibitors: all showed encouraging results. Most clinical trials and guidelines do not specify what the optimal approach is for patients with HCL in special situations as elderly population above 80 years old, very young patients below 40 years old, pregnant women, and when leukemia is presented with other comorbidities as active infection or vasculitis.Key messages: In this current manuscript, we summarized our approach to HCL in the era of novel agents with special emphasis on age and comorbidities.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-10"},"PeriodicalIF":1.1,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increased Prevalence of Thromboembolic Events in Patients with Congenital Dyserythropoietic Anemia Type I. 先天性促红细胞增生性贫血I型患者血栓栓塞事件发生率增高

IF 1.1 4区医学

Acta Haematologica Pub Date : 2025-07-30 DOI: 10.1159/000547577

Mahdi Asleh, Aya Khalaila, Yotam Eshel, Kayed Al-Athamen, Joseph Kapelushnik, Hagit Miskin

{"title":"Increased Prevalence of Thromboembolic Events in Patients with Congenital Dyserythropoietic Anemia Type I.","authors":"Mahdi Asleh, Aya Khalaila, Yotam Eshel, Kayed Al-Athamen, Joseph Kapelushnik, Hagit Miskin","doi":"10.1159/000547577","DOIUrl":"10.1159/000547577","url":null,"abstract":"Introduction: Congenital dyserythropoietic anemia type I (CDA-I) is a rare disorder of erythropoiesis. All CDA-I patients are expected to have iron overload and chronic hemolysis. Patients with severe anemia may undergo splenectomy. Hemochromatosis, chronic hemolysis, and splenectomy are all found to increase risk for thromboembolism in thalassemic patients. As CDA-I patients have similar findings, we sought to evaluate prevalence of thromboembolic events (TEEs) in these patients.Methods: A retrospective case-control study was conducted, including 110 CDA-I patients (study group) and 326 age- and sex-matched iron deficiency anemia patients of the same ethnicity (control group). Patients were risk-stratified using Risk Assessment Models for thromboembolism.Results: We identified 3 cases (2.7%) with TEEs in the CDA group and 1 case (0.3%) in the control group. All patients were females. VTE risk scores were low to moderate for CDA patients and higher for IDA patient. When compared to control group, CDA-I patients were nine times more likely to develop TEE (OR 9.11, 95% CI = 1.15-185.27, p = 0.057). All 3 CDA patients had a history of remarkable hemolysis and iron overload. Two underwent splenectomy.Conclusion: These findings show that CDA patients appear to be at increased risk for TEEs.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-10"},"PeriodicalIF":1.1,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144752031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in Acute Lymphoblastic Leukemia Review Series. 急性淋巴细胞白血病进展综述系列。

IF 1.1 4区医学

Acta Haematologica Pub Date : 2025-07-29 DOI: 10.1159/000547659

Jayastu Senapati, Nicholas J Short

引用次数: 0

Future Directions in Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. 同种异体干细胞移植治疗急性淋巴细胞白血病的未来研究方向。

IF 1.1 4区医学

Acta Haematologica Pub Date : 2025-07-25 DOI: 10.1159/000547644

Natalie Rafaeli, Partow Kebriaei

{"title":"Future Directions in Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia.","authors":"Natalie Rafaeli, Partow Kebriaei","doi":"10.1159/000547644","DOIUrl":"10.1159/000547644","url":null,"abstract":"Background: Allogeneic stem cell transplantation (ASCT) has been a cornerstone of acute lymphoblastic leukemia (ALL) treatment for decades, with significant improvements in patient survival. These advancements are linked to better therapies, refined conditioning regimens, and minimal residual disease monitoring. Despite progress, challenges remain in reducing relapse, treatment-related mortality, and toxicity.Summary: This article explores recent advancements in ASCT for ALL, focusing on conditioning regimens, graft engineering, and post-transplant therapies. Key developments include identifying patients who benefit from reduced-intensity conditioning over myeloablative conditioning or reduction in dose of total body irradiation (TBI), leading to improved outcomes and lower toxicity. Innovative graft manipulation strategies, such as Orca-T and Orca-Q, aim to enhance graft-versus-leukemia effects while minimizing graft-versus-host disease (GVHD). Additionally, post-transplant therapies, including targeted treatments, immunotherapies, and CAR-T cells, are showing promise in preventing relapse. Advances in mismatched donor use and GVHD prophylaxis are broadening donor options and reducing adverse effects, improving ASCT's safety and effectiveness in ALL.Key messages: ASCT remains a critical treatment for high-risk ALL, with advancements in conditioning, graft engineering, and post-transplant strategies. Future focus will be on optimizing patient selection, use in post-CAR-T consolidation, and refining graft manipulation, aiming to personalize ASCT and enhance survival and quality of life for ALL patients.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-8"},"PeriodicalIF":1.1,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144726425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond CAR-T: The Rise of CAR-NK/T Cells for Haematological Cancer. 超越CAR-T: CAR-NK/T细胞在血液学癌症中的崛起。

IF 1.1 4区医学

Acta Haematologica Pub Date : 2025-07-24 DOI: 10.1159/000547531

Mohammadamin Noorafrooz, Robert Peter Gale, Mohadese Dashtkoohi

引用次数: 0

Global Challenges in Paediatric Acute Lymphoblastic Leukaemia. 儿童急性淋巴细胞白血病的全球挑战。

IF 1.1 4区医学

Acta Haematologica Pub Date : 2025-07-22 DOI: 10.1159/000547506

Shekhar Krishnan, Vaskar Saha

{"title":"Global Challenges in Paediatric Acute Lymphoblastic Leukaemia.","authors":"Shekhar Krishnan, Vaskar Saha","doi":"10.1159/000547506","DOIUrl":"10.1159/000547506","url":null,"abstract":"Background: Acute lymphoblastic leukaemia (ALL) is the commonest paediatric cancer and represents a fifth of adult leukaemias. Global outcome disparities are linked to variations in socio-demographic indices (SDIs).Summary: In high-SDI regions, established collaborative groups report cure rates surpassing 90% in paediatric ALL. The focus is on reducing treatment toxicity using chemotherapy-free strategies, principally T-cell-directed immunotherapies and targeted small molecules, as exemplified in adult Philadelphia-chromosome-positive ALL. High cure rates limit testing of novel approaches outside niche subgroups, while high costs preclude wider real-world adoption of these advances. Mid-SDI regions (50-80% cure) face challenges in fully implementing contemporary risk-adapted therapy to improve outcomes and reduce costs. This necessitates collaborative practice, standardised high-quality risk-stratification diagnostics, and access to quality-assured generic cytotoxics. Low-SDI regions (<50% cure) report rising disease burden and face more fundamental challenges, including timely diagnosis, access to treatment and expertise, and minimising toxicity and abandonment. Solutions require locally adapted protocols, collaborative partnerships, and sustained patient-support programmes.Key message: Global partnerships across SDI regions are crucial to address shared challenges in ALL, including access to affordable quality therapeutics, continuing refinement of established treatment elements, tailoring biomarkers for diverse populations, and collaborative frameworks to evaluate new treatments, technologies, and treatment paradigms.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-9"},"PeriodicalIF":1.1,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study. 鲁索利替尼治疗早发性或加重性贫血对骨髓纤维化患者的影响：JUMP研究的事后分析

IF 1.1 4区医学

Acta Haematologica Pub Date : 2025-07-18 DOI: 10.1159/000546585

Haifa Kathrin Al-Ali, Paola Guglielmelli, Claire N Harrison, Ruben A Mesa, J E Hamer-Maansson, Evan Braunstein, Vikas Gupta

{"title":"Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study.","authors":"Haifa Kathrin Al-Ali, Paola Guglielmelli, Claire N Harrison, Ruben A Mesa, J E Hamer-Maansson, Evan Braunstein, Vikas Gupta","doi":"10.1159/000546585","DOIUrl":"10.1159/000546585","url":null,"abstract":"Introduction: Anemia can influence decisions regarding initiation, dosing, and discontinuation of Janus kinase inhibitor therapy for myelofibrosis. We evaluated the impact of new-onset or worsening anemia following ruxolitinib initiation on spleen response, symptom severity, and overall survival in patients with myelofibrosis.Methods: This post hoc analysis used data from all patients enrolled in the phase 3b JUMP trial. Outcomes were stratified by presence or absence of new-onset or worsening anemia following ruxolitinib initiation, defined as hemoglobin decrease ≥15 g/L from baseline and hemoglobin <100 g/L (female)/<110 g/L (male) at Week 12, new transfusion requirement post-baseline until Week 12 (for baseline non-transfusion-dependent patients), or ≥50% increase from baseline in red blood cell transfusions through Week 12.Results: Overall, 2,233 patients were included; 52.9% developed new-onset or worsening anemia up to Week 12. Ruxolitinib was associated with improvements in spleen length and myelofibrosis symptoms, regardless of the presence or absence of new-onset or worsening anemia or baseline anemia status. No differences in spleen response or overall survival were observed between patients with versus without new-onset or worsening anemia, regardless of baseline anemia status.Conclusions: These results support the use of ruxolitinib in patients with myelofibrosis, regardless of baseline anemia or development of treatment-related anemia.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-9"},"PeriodicalIF":1.1,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and Cardiologists. BTKi治疗慢性淋巴细胞白血病患者心血管不良事件的实际管理：血液学家和心脏病学家的共识报告。

IF 1.1 4区医学

Acta Haematologica Pub Date : 2025-07-18 DOI: 10.1159/000547426

Talha Munir, Eglė Čiburienė, Vasko Graklanov, Mariana Gospodinova, Ozren Jakšić, Luka Lipar, Imelda Marton, Anna Panovská, Lucia Petríková, Regina Pileckyte, Zoltan Pozsonyi, Miroslav Slanina, Matevž Škerget, Nikola Bulj

{"title":"Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and Cardiologists.","authors":"Talha Munir, Eglė Čiburienė, Vasko Graklanov, Mariana Gospodinova, Ozren Jakšić, Luka Lipar, Imelda Marton, Anna Panovská, Lucia Petríková, Regina Pileckyte, Zoltan Pozsonyi, Miroslav Slanina, Matevž Škerget, Nikola Bulj","doi":"10.1159/000547426","DOIUrl":"10.1159/000547426","url":null,"abstract":"Background: Cardiovascular (CV) adverse events (AEs), especially atrial fibrillation (AF) and hypertension, have been reported in patients receiving treatments for chronic lymphocytic leukemia (CLL), including Bruton's tyrosine kinase inhibitors (BTKis). Although these AEs are managed effectively in most cases and AE management guidelines exist, practical management approaches are inconsistent across regions and practices. We aimed to address these inconsistencies by developing consensus recommendations.Summary: A European expert panel was assembled comprising eight hematologists and six cardiologists. Literature analysis, expert interviews, and the Delphi method were used to gain consensus on screening, monitoring, and treatment of AF and hypertension statements.Key messages: Maintaining BTKi treatment is paramount to maximize time to next treatment; for patients at high risk of progression, this can be achieved by appropriately treating hypertension and AF and adjusting the BTKi dose. Patients should be risk-stratified as low, moderate, high, or very-high risk of cancer therapy-related CV toxicity and treated according to their disease status so that CLL treatment can be maintained. Patient education on symptom monitoring, home blood pressure monitoring, and electrocardiograms (baseline, every 3 months) are recommended to detect/monitor AF and hypertension. Close collaboration between hematologists and cardiologists is vital to achieve optimal patient outcomes.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-16"},"PeriodicalIF":1.1,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0